From the FDA Drug Label
Buspirone hydrochloride tablets are contraindicated in patients hypersensitive to buspirone hydrochloride. The use of monoamine oxidase inhibitors (MAOIs) intended to treat depression with buspirone or within 14 days of stopping treatment with buspirone is contraindicated because of an increased risk of serotonin syndrome and/or elevated blood pressure. The use of buspirone within 14 days of stopping an MAOI intended to treat depression is also contraindicated. Starting buspirone in a patient who is being treated with reversible MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome.
The contraindications for Buspar (Buspirone) are:
- Hypersensitivity to buspirone hydrochloride
- Use of monoamine oxidase inhibitors (MAOIs) intended to treat depression with buspirone or within 14 days of stopping treatment with buspirone
- Use of buspirone within 14 days of stopping an MAOI intended to treat depression
- Starting buspirone in a patient who is being treated with reversible MAOIs such as linezolid or intravenous methylene blue 1
From the Research
Contraindications for Buspar (Buspirone)
- The provided studies do not directly address the contraindications for Buspar (Buspirone) 2, 3, 4, 5, 6.
- However, study 2 discusses the pharmacokinetics of buspirone in patients with renal or hepatic impairment, suggesting that buspirone may not be suitable for patients with severe renal or hepatic impairment.
- Study 5 provides a general guide for prescribing medications in patients with cirrhosis, but does not specifically mention buspirone as a contraindicated medication.
- Studies 3, 4, and 6 do not provide relevant information on the contraindications of buspirone.
- Based on the available information, it appears that buspirone may be contraindicated in patients with severe renal or hepatic impairment, but further research is needed to confirm this 2.
Potential Interactions
- Buspirone may interact with other medications, such as monoamine oxidase inhibitors (MAOIs), which can increase the risk of adverse reactions 3.
- However, the provided studies do not specifically address the contraindications for buspirone in relation to these interactions.
Renal and Hepatic Impairment
- Study 2 suggests that buspirone may not be suitable for patients with severe renal or hepatic impairment due to altered pharmacokinetics.
- However, the study does not provide clear contraindications for buspirone in these patient populations.